Mesoblast Limited (ASX: MSB) announced that the independent Data Monitoring Committee (DMC) supervising the Phase 3 trial of Revascor for advanced chronic heart failure held their tenth and final scheduled meeting.
The committee has recommended the trial to continue as scheduled. The cardiovascular results trial has started final review visits for all patients that are alive with a target of last patient being Jan 2020 end.
AR AEDT: 2:07 PM, MSB shares are trading at $1.93, up 0.521% from its previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.